Organovo delivers 3D Liver tissue ahead of schedule; shares jump


Organovo (ONVO) has delivered the first 3D Liver tissue to a laboratory outside of the company to a "key opinion leader" for experimentation.

The target date for the milestone had been April; Organovo expects to have bioprinted almost 400 3D Liver tissues during January.

Organovo also intends to launch its 3D Liver tissue product and generate revenues before December; previously, the company's target had been the end of that month.

Shares +6.7%.  (8-K)

From other sites
Comments (10)
  • alfredocamera
    , contributor
    Comments (16) | Send Message
     
    It will be intersting to know the Laboratory Name.
    Btw it is a great news.
    29 Jan 2014, 07:51 AM Reply Like
  • temenem
    , contributor
    Comments (539) | Send Message
     
    GOOD news, but being ahead of schedule is not BIG news. :-)
    29 Jan 2014, 08:33 AM Reply Like
  • deckmaker12
    , contributor
    Comments (47) | Send Message
     
    All those shorts and negative articles are I bet hurting. Glad I got back in under $9 last week.
    29 Jan 2014, 08:47 AM Reply Like
  • tinsley09
    , contributor
    Comments (339) | Send Message
     
    Will their product be more durable and have broader applications to pharmacology than others on the market.?
    29 Jan 2014, 09:01 AM Reply Like
  • joelkatz
    , contributor
    Comments (566) | Send Message
     
    ...Than others on the market,

     

    Please elaborate which others there are on the market, 3D Liver tissue, Thanks
    29 Jan 2014, 10:16 AM Reply Like
  • tinsley09
    , contributor
    Comments (339) | Send Message
     
    Please see the recent barrage of negative "short" comments and articles by Pierson ect, ect, .in Seeking Alpha in the last 6 months.
    These were written by people who have no concept of how a disruptive technology can impact a domain(testing for liver toxins etc) and the promising field of regenerative medicine, as elaborated in the Economist 2 years ago.Their short term obessive focus on RISK ,clouded their capacity to think in broader dimensions when modelling a disruptive technology's market trajectory for INVESTMENT.It is not worth the energy,implicated in storing their names or comments in memory.
    29 Jan 2014, 12:03 PM Reply Like
  • Moustafa911
    , contributor
    Comments (2) | Send Message
     
    Great news, but still need to know the "key opinion leader" opinion !
    29 Jan 2014, 09:05 AM Reply Like
  • Macattack1668
    , contributor
    Comments (2) | Send Message
     
    KOL is the company
    Read the 8-K
    29 Jan 2014, 09:05 AM Reply Like
  • flyer777
    , contributor
    Comments (24) | Send Message
     
    Keith Murphy is scheduled to be on Fox Business with Mellisa Francis today at 5:00 EST.
    Things could get interesting since short interest rose from 8.6 million to 11.2 million shares.
    In response to tinsley09, consider that the tissue not only lasts for 40 day it also responds to toxins that are detrimental to the liver such as acetaminophen. This allows pharmaceutical companies to perform early testing on potential drugs at substantial savings.
    29 Jan 2014, 10:02 AM Reply Like
  • jvallancourt@aol.com
    , contributor
    Comments (3) | Send Message
     
    Not certain who makes the bioprinters. Please comment...
    29 Jan 2014, 01:34 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs